Articles

International senior biopharma professionals gather in London to deconstruct deal trends and get the low-down and insider knowledge of successful partnering deals at this leading European bio-partnering event

In light of shrinking product pipelines, decreasing product density and an overall scarcity of financing for early stage innovation, biopharma leaders need to nail the right strategy that will be conducive to successful, long-term innovation and new product creation.

For the first time ever Roche and Genentech speak candidly and off the record of what it took to bring to completion the biggest fusion witnessed by the pharma industry in recent times, and appraise the past two years to provide attendees at this key European bio-partnering conference with an "how to" guide for future mergers and alliances, ensuring that a culture of innovation is maintained.

With countless deal proposals never reaching successful completion, knowing what it takes to achieve cut through is a must. GSK, Celgene, Pfizer and more talk through a complete checklist of what is needed to achieve successful engagement with biopharma, from the initial point of contact through to deal completion.

About BioBusiness 2012:

BioBusiness 2012 is not about the standard commercial messages that you'll typically hear at other events and more about panels and unique off-the-record case studies cutting through to the issues/solutions that are going to drive the industry forward, prompting lively and incisive debate amongst industry leaders. 65+ global biopharma leaders will speak at this leading European bio-partnering event and over 250 senior decision makers will talk and do business. There is no better forum to get face to face time with the people that matter.

For more information about BioBusiness 2012 visit www.biobusiness-conference.com, email biobusinesswbr.co.uk or call +44 (0) 207 368 9465

BioBusiness 2012, Radisson Blu, London, 31st Jan - 2 2nd February 2012

To make any comments on this article, or to ask a question of the author, please contact the publisher. If you would like to submit an article please subscribe to our Pharmalicensing Intelligence service.

The opinions expressed in the articles published in this section do not necessarily reflect those of Innovaro Pharmalicensing or Innovaro Corporation. No actions including proposals to or agreements with other companies should be taken by any reader without obtaining specific business or legal advice. Neither the publisher nor the authors accept any liability for any actions or activities undertaken by any reader or other third party as a consequence of these articles or for any errors or omissions therein.